InDex Pharmaceuticals gets new patent for cobitolimod granted in the US
November 9, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the United States Patent and Trademark Office (USPTO). The patent provides protection for the use of certain dosage regimens of cobitolimod for treating inflammatory bowel disease, including the 250 mg dose which was successful in the phase IIb study CONDUCT.The patent, entitled Cobitolimod for use in the treatment of inflammatory bowel disease (patent number 11166975), will provide an exclusivity period until May 2038, with the